Author

Isabelle Sermadiras

AstraZeneca (United Kingdom)ORCID 0000-0002-9443-9131Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:graph neural network· 1 Approach:machine learning (classical)· 1 Assay:protein sequence· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

A N M Nafiz AbeeriD· 1 shared Gilad KaplaniD· 1 shared James SaveryiD· 1 shared Jenna G CaldwelliD· 1 shared Maryam PouryahyaiD· 1 shared Mehdi Boroumand· 1 shared Neil ModyiD· 1 shared Rebecca Croasdale-WoodiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioinformatics

A N M Nafiz AbeerORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Accelerating Antibody Development: Sequence and Structure-Based Models for Predicting Developability Properties through Size Exclusion Chromatography

A N M Nafiz Abeer, Mehdi Boroumand, Isabelle Sermadiras, Jenna G Caldwell, Valentin Stanev, Neil Mody, Gilad Kaplan, James Savery, Rebecca Croasdale-Wood, Maryam Pouryahya

This study compares sequence and structure-based models for predicting antibody developability properties using SEC assays, identifying the most effective in silico approach.

bioRxiv · Feb 2, 2025 · PreprintBioinformatics